Richmond Pharmacology host ground breaking Early Phase Trials Integration seminar at the Royal Society of Medicine

Posted:
22
December 2005

Richmond Pharmacology host ground breaking Early Phase Trials Integration seminar at the Royal Society of MedicineThe Early Phase Trials Integration seminar held recently at the Royal Society of Medicine was seen as a huge success by all who attended.The seminar generated valuable discussions between guest speakers and the Pharmaceutical industry, and explored innovative new ways to maximize the efficiency and speed of Early Phase research.The seminar focused on the developments around EU Legislations which have re-defined the boundaries of Phase I and opened a new era of opportunity to expedite compounds through the Early Phases.World leading expert speakers from St George's University London, Mayday University Hospital & NHS trust and the ABPI outlined the new context within which clinical trials are conducted. Presentations on innovative new methodology were reviewed to identify how a CRO like Richmond Pharmacology can add value to pharmacology and patient studies.Pharmacology and patient studies can now be integrated or work independently of one another. Clinical & therapeutic innovations enable Early Phase research to deliver more dynamic and insightful studies, maximizing the probability of a compound reaching the later Phases.This new era of Early Phase research demands 3 foundations which were explored during the day:

  1. Commercial in- and out-patient facilities
  2. Acute NHS environment
  3. Therapeutic expertise

Delegate feedback has been positive. Everyone who attended benefited from the highly informative and educational day which was also accredited by the Faculty of Pharmaceutical Medicine (FPM).View presentations from the seminar

Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021
Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.
View event

Novel rate-controlled fentanyl patch shows promise in phase I clinical trial

April 1, 2021
Our expertise in ethnic differences and access to over 12,000 first generation Japanese volunteers accelerated our ability to provide robust clinical trial data to support future applications of new chronic pain medicines to the Japanese drug market.
Read more

A new era for UK-Japanese scientific relations

March 23, 2021
Dr Taubel uses his experience of conducting more than 60 Japanese bridging studies to explain why the deal is of strategic importance to the UK and highlights the scientific requirements for conducting successful Japanese trials abroad
Read more

Richmond Pharmacology’s local MP Neil Coyle calls on the Government to evaluate the potential of using Clinical Research Organisations.

February 3, 2021
Richmond Pharmacology has offered its services to the Government and the NHS as an additional vaccine site in London
Read more